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BACKGROUND: Bladder cancer is the second most common cancer of the urinary system. Early diagnosis of this tumour and estimation
of risk of future progression after initial transuretherial resection have a significant impact on prognosis. Although there are several
molecular markers for the diagnosis and prognosis for this tumour, their accuracy is not ideal. Previous reports have shown that
UHRF1 (ubiquitin-like with PHD and ring-finger domains 1) is essential for cellular proliferation. In this study, we examined whether
UHRF1 can be a novel molecular marker of bladder cancer.
METHODS: We performed real-time TaqMan quantitative reverse transcription–PCR and immunohistochemistry to examine
expression levels of UHRF1 in bladder and kidney cancers.
RESULTS: Significant overexpression of UHRF1 was observed in bladder cancer. The overexpression was correlated with the stage and
grade of the cancer. Although UHRF1 expression in muscle-invasive cancer was greater than in non-invasive (pTa) or superficially
invasive (pT1) cancers, UHRF1 could still be detected by immunohistochemistry in these early-stage cancers. Overexpression of
UHRF1 in bladder cancer was associated with increased risk of progression after transurethral resection. High expression of UHRF1 in
kidney cancer was also observed. But the increased levels of UHRF1 in kidney cancer were less significant compared with those in
bladder cancer.
CONCLUSION: Our result indicates that an immunohistochemistry-based UHRF1 detection in urine sediment or surgical specimens can
be a sensitive and cancer-specific diagnostic and/or prognosis method, and may greatly improve the current diagnosis based on
cytology.
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Bladder cancer is the second most common cancer of the urinary
system. Approximately 356600 new cases of bladder cancer are
diagnosed each year worldwide and, in terms of overall
cancer frequency, it is ranked as ninth (International Agency for
Research on Cancer, The GLOBOCAN 2002 database, http://
www-dep.iarc.fr/). According to Cancer Research UK (http://www.
cancerresearchuk.org/), bladder cancer is the fourth most common
cancer in males in the United Kingdom. The highest rates of
bladder incidence are found in industrially developed countries,
particularly in North America and Western Europe (Parkin et al,
2005). In these countries, approximately 90% of bladder tumours
are transitional cell carcinomas (TCCs), whereas the remaining
10% are squamous cell carcinomas and adenocarcinomas (Stein
et al, 2001).
There are several potential biomarkers for diagnosis and
prognosis for bladder cancer, including nuclear matrix protein-
22 (NMP-22), human complement factor H-related protein,
telomerase, fibrin degradation product, and hyaluronic acid
(Dey, 2004). Among these, only two biomarkers, NMP-22 and
human complement factor H-related protein, are in clinical use.
Although these two markers are in clinical use, sensitivity and
specificity of these markers are not perfect (van Rhijn et al, 2005);
NMP-22 staining shows false-positivity reactions in patients with
haematuria, and the BTA stat/BTA TRAK assay, which detects
human complement factor H-related protein, shows false-positiv-
ity reactions in patients with urinary tract inflammation, recent
genitourinary tumours and in cases of bladder stone (Dey, 2004).
Cytology is still the most accurate diagnosis method, although
sensitivity is not enough high (van Rhijn et al, 2005). Thus,
discovery of a novel biomarker, which is sensitive and specific for
bladder cancer, is an urgent subject.
Kidney cancer, which accounts for 2–3% of all adult malignant
neoplasms, is the most lethal of the urologic cancers. Traditionally,
more than 40% of patients with kidney cancer have died of their
cancer, in contrast with the 20% mortality rates associated with
prostate and bladder carcinomas (Pantuck et al, 2001). In 2007,
two molecular targeting drugs, sorafenib and sunitinib, were
approved by the Food and Drug Administration of the United
States Department of Health and Human Service, and are in
clinical use. These two drugs are tyrosine kinase inhibitors that
have antitumor activity in advanced renal cell carcinoma. They
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smay improve the mortality rates of this cancer, although these
drugs have side effects, such as hand–foot syndrome, rash, fatigue,
hypertension, and diarrhoea (Grandinetti and Goldspiel, 2007).
Current diagnosis mainly relies on ultrasound and computed
tomographic-scan. There are no good diagnostic and prognostic
markers for kidney cancer.
UHRF1 (ubiquitin-like with PHD and ring-finger domains 1),
also known as ICBP90, was identified as a protein, whose
expression is only detectable in proliferating cells, not in quiescent
cells (Hopfner et al, 2000; Unoki et al, 2004). Recently, it was
revealed that UHRF1 plays a central role in transferring DNA
methylation status from mother cells to daughter cells. Its SET and
RING finger-associated (SRA) domain recognises hemimethylated
DNA that appears in newly synthesised daughter DNA strands
during duplication of DNA strands through the S phase (Arita
et al, 2008; Avvakumov et al, 2008; Hashimoto et al, 2008). The
UHRF1 recruits DNA methyltransferase 1 (DNMT1) to the site
with proliferating cell nuclear antigen (PCNA) and methylates the
newly synthesised strands (Sharif et al, 2007; Achour et al, 2008).
The UHRF1 promotes G1/S transition (Arima et al, 2004; Jeanblanc
et al, 2005) and is a direct target of E2F transcription factor 1
(E2F1) (Mousli et al, 2003; Unoki et al, 2004; Abbady et al, 2005).
The tumour suppressor p53, which is deficient in 50% of all human
cancers (Hussain and Harris, 2000), indirectly downregulates
UHRF1 through the upregulation of p21/WAF1 and subsequent
deactivation of E2F1 (Arima et al, 2004). Expression of UHRF1 is
upregulated in various cancers, including breast, prostate, lung,
astrocytomas, pancreatic cancers, and cervical cancer (Mousli
et al, 2003; Unoki et al, 2004; Crnogorac-Jurcevic et al, 2005;
Jenkins et al, 2005; Lorenzato et al, 2005; Oba-Shinjo et al, 2005).
Overexpression of UHRF1 in these cancers may be partially due
to the inactivation of p53, although there are most probably
several pathways which regulate UHRF1. Knockdown of UHRF1
expression in cancer cells suppressed cell growth significantly,
indicating that UHRF1 is essential for progression of cancers
(Unoki et al, 2004).
Here, we report that the overexpression of UHRF1 in bladder
tumour is associated with malignant potential of the cancers as
defined by the stage and grade (Lopez-Beltran, 2008). The UHRF1
can be detected in tissue samples and urine sediment from patients
with bladder cancer, and thus can be a diagnostic and/or
prognostic marker.
MATERIALS AND METHODS
Tissue samples and RNA preparation
A total of 124 surgical specimens of primary urothelial carcinoma
were collected (Table 1), either by cystectomy or transurethral
resection of bladder tumour (TURBT), and snap-frozen in liquid
nitrogen. Twenty-one specimens of normal bladder urothelial
tissue were collected from the areas of macroscopically normal
bladder urothelium in patients with no evidence of malignancy.
Five sequential sections of 7mm thick were cut from each tissue
and stained using Histogene staining solution (Arcturus, Oxnard,
CA, USA) following the manufacturer’s protocol, and assessed for
cellularity and tumour grade by an independent consultant
urohistopathologist. Slides were then transferred for microdissec-
tion using a Pix Cell II laser capture microscope (Arcturus). This
technique uses a low-power infrared laser to melt a thermoplastic
film over the cells of interest, to which the cells become attached.
Approximately 10000 cells were microdissected from both
stromal and epithelial/tumour compartments in each tissue. RNA
was extracted using an RNeasy Micro Kit (Qiagen, Crawley, UK).
Areas of cancer or stroma containing significant inflammatory cell
infiltration were avoided to prevent contamination (Wallard et al,
2006). Total RNA was treated with DNase and then quantitative
reverse transcription–PCR (qRT–PCR) was performed as
described below. Given the low yield of RNA from such small
samples, NanoDrop quantification was not performed, but
correction for the endogenous 18S cycle threshold (CT) value
was used as an accurate measure of the amount of intact starting
Table 1 Base line characteristics of bladder tumour patients used for
TaqMan real-time quantitative RT–PCR analyses
Characteristics n (%)
a
Total numbers of patients 124
Anatomic site
Bladder 112 (90)
Upper tract 12 (10)
Type
TCC 122 (499)
Others 1 (o1)
Invasiveness
Superficial 71 (63)
Invasive 41 (37)
T-category
Ta 40 (35)
T1 32 (28)
T2 24 (21)
T3 14 (12)
T4 4 (4)
WHO grading
Grade I 9 (8)
Grade II 59 (51)
Grade III 47 (41)
Risk after TURBT
Low 7 (13)
Intermediate 26 (46)
High 23 (41)
Sex
Male 75 (72)
Female 29 (28)
Numbers of tumours
o4 53 (85)
44 9 (15)
Tumour size
o5 38 (66)
45 20 (34)
Growth pattern
CIS 1 (2)
Papillary 32 (52)
Solid 19 (31)
Solid/papillary 9 (15)
Recurrence
No 19 (29)
Yes 46 (71)
5-year survival
Alive 46 (49)
Dead 48 (51)
Smoking
Non-smoker 22 (35)
Smoker 40 (65)
CIS, carcinoma in situ; TCC, transitional cell carcinomas; RT–PCR, reverse
transcription–PCR; TURBT, transurethral resection of the bladder tumour.
aTotal
numbers of the patients are not always 123, because not all patients have all the
clinical information.
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sRNA. To validate the accuracy of microdissection, primers and
probes for Vimentin and Uroplakin were sourced, and qRT–PCR
was performed according to the manufacturer’s instructions
(Assays on demand, Applied Biosystems, Warrington, UK).
Vimentin is primarily expressed in mesenchymally derived cells,
and was used as a stromal marker. Uroplakin is a marker of
urothelial differentiation and is preserved in up to 90% of
epithelially derived tumours (Olsburgh et al, 2003).
Seventy-two kidney tumours (Supplementary Table 1), 6
oncocytomas, and 21 normal kidneys were collected from the
Department of Urology in Addenbroke’s hospital. Complementary
DNAs (cDNAs) from 12 normal tissues and paraffin-embedded
tissue slides for immunohistochemistry described below were
purchased from BioChain Institute (Hayward, CA, USA). A
paraffin-embedded tissue slide (Case 1 in Figure 2) is obtained
from Iwate Medical University with written informed consent
(Takata et al, 2007). Detailed information of clinical samples on
the slides is shown in Supplementary Table 2–4. Use of tissues for
this study was approved by Cambridgeshire Local Research Ethics
Committee (Ref 03/018). We have removed the possibility of
genomic DNA contamination by PCR using a primer set that can
amplify genomic DNA (data not shown).
TaqMan real-time qRT–PCR
For TaqMan real-time qRT–PCRs, specific primers and probes,
which strictly amplify only cDNA not genomic DNA, for human
UHRF1 and b2-microglobulin were purchased from Applied
Biosystems (Carlsbad, CA, USA; ID: Hs00273589_m1, and
4333766F, respectively). The PCRs were performed using the ABI
Prism 7700 Sequence Detection System (Applied Biosystems)
following the manufacturer’s protocol. Amplification conditions
were 2min at 501C, 10min at 951C and then 40 cycles each
consisting of 15s at 951C and 1min at 601C. The CT value
obtained by UHRF1 amplification was compared among the
samples after normalisation using b2-microglobulin expression
levels as an endogenous control.
Statistical analysis
Kruskal–Wallis test was performed for comparison of the UHRF1
expression levels among three or more different groups. Mann–
Whitney U-test nonparametric analysis was performed for
comparison of the UHRF1 expression levels between two groups.
P-value of 0.05 or less was considered significant.
Immunohistochemical staining analysis
The expression patterns of UHRF1 and p53 in bladder tumours,
and normal human tissues were examined by immunohistochem-
istry as described previously (Unoki et al, 2004). Briefly, slides of
paraffin-embedded bladder tumour specimens and normal human
tissues (the bladder, heart, liver, kidney, and lung) were processed
under high pressure (1251C, 30s) in antigen-retrieval solution,
high pH 9 (S2367, Dako Cytomation, Carpinteria, CA, USA),
treated with peroxidase blocking regent, and then treated with
protein blocking regent (K130, X0909, Dako Cytomation). Tissue
sections were incubated with the mouse anti-UHRF1 monoclonal
antibody (1:400, BD Bioscience, Franklin Lakes, NJ, USA) or
mouse p53 antibody (DO-1, 1:100, Santa Cruz), or normal mouse
IgG (1:100, Santa Cruz, Santa Cruz, CA, USA) followed by HRP-
conjugated secondary antibody (Dako Cytomation). Antigen was
visualised with substrate chromogen (Dako liquid DAB chromo-
gen; Dako Cytomation). Finally, tissue specimens were stained
with Mayer’s haematoxylin (Muto pure chemicals Ltd, Tokyo,
Japan) for 20s to discriminate the nucleus from the cytoplasm.
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Figure 1 Expression levels of UHRF1 mRNA in urinary system tumours and normal tissues detected by TaqMan real-time qRT–PCR. Expression of
UHRF1 in 12 different normal tissues, 21 normal kidneys, 6 oncocytomas, 71 kidney tumours, 21 normal bladders, and 124 bladder tumours, including 112
bladder located cancers and 12 transitional cell carcinoma occurred in the upper tract, were compared. Expression of UHRF1 differed among the seven
groups (Po0.0001, Kruskal–Wallis’ test). Expression of UHRF1 in the kidney tumours was higher than that in the normal kidneys and also in the
oncocytomas significantly (Po0.0001 and 0.0206, respectively, Mann–Whitney’s U-test), but expression levels of UHRF1 in the bladder tumours were much
higher than those in the kidney tumours (Po0.0001, Mann–Whitney’s U-test). Among the bladder cancers, expression of UHRF1 was significantly high in the
upper tract TCCs (n¼11) compared with the bladder-origin bladder tumours (n¼112) (Mann–Whitney’s U-test; P¼0.0042). b2-microglobulin was used
for normalisation. Asterisk indicates statistically significant P-values.
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UHRF1 mRNA was highly expressed in urinary system
tumours, but not in a benign neoplasm of kidney and
several other normal tissues
Expression levels of UHRF1 in six oncocytomas (benign neoplasm
in kidney), 71 kidney tumours (Supplementary Table 1), and 124
bladder tumours (Table 1) including 11 upper tract TCCs from UK
patients were examined by TaqMan real-time qRT—PCR. As
controls, 21 normal kidneys, 21 normal bladders, and other 12
normal tissues (the brain, breast, colon, oesophagus, eye, heart,
liver, lung, pancreas, rectum, spleen, and stomach) were examined.
The UHRF1 was significantly overexpressed in bladder tumours
(Po0.0001, Mann–Whitney’s U-test, Figure 1), especially in 12
upper tract TCCs (Po0.0001, Kruskal–Wallis test, Figure 1): 10
percentile of the upper tract TCCs is higher than 50 percentile of
the bladder-origin bladder cancers. The stages of the upper tract
TCCs were as follows: four patients with pT1, one patient with pT2,
four patients with pT3, two patients with pT4, and one of unknown
stage. The grade of the upper tract TCC was as follows: eight
patients with grade II and four patients with grade III. Because all
four patients with pT1 also showed high expression of UHRF1, this
high expression of UHRF1 may correlate with the origin of
anatomic sites, besides the levels of malignancies as we described
below. Base line characteristics of the bladder tumour patients are
shown in Table 1. Next, we compared UHRF1 expression in
bladder tumours with that in 12 normal tissues, 21 normal kidneys,
6 oncocytomas, and 72 kidney tumours (Figure 1). Expression
levels of UHRF1 in the oncocytomas and in normal kidney were
not different statistically (P¼0.9535). In contrast, expression of
UHRF1 in kidney tumours was significantly increased compared
with in normal kidney and in oncocytomas (Po0.0001 and 0.0206,
respectively). However, the levels of upregulation of UHRF1 in
bladder tumours were much higher than that in kidney tumours
(Po0.0001), suggesting that UHRF1 might be a sensitive tool for
detection of bladder tumours, especially the upper tract TCCs,
which are currently often found in advanced stages.
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×400
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Figure 2 Immunohistochemical staining of UHRF1 in 13 bladder tumour cases. (A) Expression of UHRF1 in 11 transitional cell carcinomas and
two adenocarcinomas with the different stage and grade. High expression of UHRF1 was detected only in nucleus of cancer cells, not in stromal cells.
(B) Expression of UHRF1 in normal tissues including the bladder, lung, liver, heart, and kidney. No expression was observed in these normal tissues. Original
magnifications,  200 (top), and  400 (bottom). (C) Representative images of normal IgG staining as a negative control (Case 11 used for Figure 2A).
Original magnifications,  200 (top), and  400 (bottom).
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sOverexpression of UHRF1 was further confirmed in bladder
tumours from 36 Japanese patients by microarray analysis (Takata
et al, 2005, 2007). Expression of UHRF1 in these bladder tumours
was compared with the corresponding adjacent normal tissues
from the same patients, and tumour/normal ratio was obtained. In
the result, UHRF1 was overexpressed more than twice in 86% of these
bladder-cancer cases (data not shown), indicating that overexpression
of UHRF1 in bladder cancer is probably common worldwide.
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Figure 3 Expression of UHRF1 in kidney cancer. (A) UHRF1 expression in kidney cancers examined by immunohistochemistry. Clinical information of
each individual is shown in Supplementary Table S3. Magnification level is  400. (B) Expression levels of UHRF1 correlate with 5-year survival rate of kidney
tumours detected by TaqMan qRT–PCR. Patients were categorised into two groups by expression levels of UHRF1. The UHRF1 high expression group is a
group, which expresses UHRF1 eight or more (X8) and the low expression group is a group, which expresses UHRF1 less than eight-fold (o8) compared
with average of UHRF1 expression level in normal kidney from 21 individuals as 1.0. In the result of Kaplan–Meier survival analysis, the UHRF1 high
expression group showed significantly poor survival rate compared with the UHRF1 low expression group (P¼0.0096: Log-rank test). b2-microglobulin was
used for normalisation. (C) Expression levels of UHRF1 correlated with histological grade of kidney tumours detected by TaqMan qRT–PCR. Patients were
categorised into four groups by histological grade (1 to 4). High expression of UHRF1 correlated with advanced grade (P¼0.0093: Kruskal–Wallis’s test).
b2-microglobulin was used for normalisation. (D) Expression levels of UHRF1 correlated with pathological staging and histological grade of renal cancers
detected by TaqMan qRT–PCR. Patients were categorised into three groups with pathological stages, pT1 to pT3. High expression of UHRF1 correlated
with advanced stage (P¼0.0005: Kruskal–Wallis’s test). b2-microglobulin was used for normalisation.
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at the protein level
Overexpression of UHRF1 in bladder tumours was confirmed at
the protein level by immunohistochemistry. Thirteen cases of
bladder tumours including 11 cases of TCC and two cases of
adenocarcinoma were examined. Detailed clinical information
of each case is shown in Supplementary Table 2. Expression of
UHRF1 was observed only in cancer cells, not in stromal cells
(Figure 2A). Expression of UHRF1 was detectable even in bladder
tumours at non-advanced stages (grades I and II, pTa/pT1N0M0),
although stronger UHRF1 staining was detected in bladder
tumours of more advanced stages (pT2–pT4), and grades (grades
II and III). No UHRF1 staining was observed in normal tissues
including the bladder, lung, liver, heart, and kidney (Figure 2B,
Supplementary Table 3). Normal mouse IgG was served as a
negative control in each case. Figure 2C shows a representative
datum. We also performed immunohistochemistry using the
kidney specimens. Staining in kidney tumours was weak compared
with bladder tumours (Figure 3A and Supplementary Table 4),
although overexpression of UHRF1 at the mRNA level was
associated with several characteristics of kidney tumour patients,
including 5-year survival rates, pathological staging, and histolo-
gical grade (Figure 3B and C, Supplementary Table 1).
Expression of UHRF1 correlated with the stage and grade
of bladder tumours, and the risk of recurrence and
progression after TURBT
Although expression of UHRF1 was not associated with difference
of gender, numbers of tumour, tumour size, growth pattern
(papillary or solid), incidence of recurrence, survival status after
5 years from surgery, and smoking history (P40.05, Mann–
Whitney’s U-test, Supplementary Figure 1), we found that the
expression of UHRF1 correlated with stages (pTa–pT4) and grades
(grades I–III) (Figure 4A and B). Expression levels of UHRF1 in
superficial bladder tumours (pTa and pT1) and invasive bladder
tumours (pT2–pT4) were both significantly higher than those in
normal bladders by Mann–Whitney’s U-test (P¼0.0063 and
0.0034, respectively). Although UHRF1 expression in invasive
bladder tumours was not significantly higher than that in
superficial bladder tumours statistically, expression of UHRF1
differed among the three groups by Kruskal–Wallis test
(P¼0.0058). Expression of UHRF1 also differed among four
groups with the different grade by Kruskal–Wallis test
(P¼0.0156): although the distribution of UHRF1 expression in
each group had a relatively wide range, the median value of UHRF1
expression in each group increased in parallel with increased
grade. Expression levels of UHRF1 in tumours of grade-II and
grade-III were upregulated compared with normal bladders by
Mann–Whitney’s U-test (P¼0.0033 and 0.0041, respectively).
Expression levels of UHRF1 in patients with the high-risk
superficial bladder cancer were higher than that found in the
low-risk group (Mann–Whitney’s U-test: P¼0.0350, Figure 4C).
DISUCUSSION
Ubiquitin-like with PHD and ring-finger domains 1 is a protein
which is overexpressed in various cancers (Mousli et al, 2003;
Unoki et al, 2004; Crnogorac-Jurcevic et al, 2005; Jenkins et al,
2005; Lorenzato et al, 2005; Oba-Shinjo et al, 2005) and the Normal
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Figure 4 Expression of UHRF1 correlated with the stage, grade, and the
risk after TURBT. (A) Expression of UHRF1 in 21 normal bladders, 71
superficial bladder tumours (T-category is pTa and pT1), and 41 invasive
bladder tumours (T-category is pT2, pT3, and pT4) detected by TaqMan
qRT–PCR. Expression levels of UHRF1 in superficial bladder tumours and
in invasive tumours were significantly higher compared with those in normal
bladders by Mann–Whitney’s U-test (P¼0.0063 and 0.0034, respectively).
Although its expression in superficial tumours and invasive tumours did not
differ (P¼0.2442, Mann–Whitney’s U-test), it differed among the three
different groups (P¼0.0058, Kruskal–Wallis’ test). b2-microglobulin was
used for normalisation. (B) Expression of UHRF1 differed among four
groups with the different grade (P¼0.0156, Kruskal–Wallis’ test) detected
by TaqMan qRT–PCR. Expression of UHRF1 in grades II and III tumour was
higher than that in the normal bladders (P¼0.0033 and 0.0041). b2-
microglobulin was used for normalisation. (C) Significant high expression of
UHRF1 in the high-risk group after TURBT (n¼23) was observed
compared with that in the low-risk group (n¼7) by Mann–Whitney’s
U-test (P¼0.0350). Asterisk indicates statistically significant P-values.
b2-microglobulin was used for normalisation.
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soverexpression is thought to be essential for malignant cancer
progression (Hopfner et al, 2000; Arima et al, 2004; Unoki et al,
2004). Thus, we examined expression of UHRF1 in urinary system
cancers collected in the United Kingdom and found that UHRF1
was moderately upregulated in the kidney tumours and signifi-
cantly overexpressed in bladder tumours, especially in the upper
tract TCCs at the mRNA level. Overexpression of UHRF1 was
further confirmed using Japanese cases, indicating that the
overexpression of UHRF1 is not specific for patients in the United
Kingdom, but common worldwide.
We verified the overexpression of UHRF1 in bladder tumour
tissues at the protein level by immunohistochemistry. Whereas, we
did not detect significant overexpression of UHRF1 in kidney
tumours at the protein level, although the high expression of
UHRF1 in kidney tumours at the mRNA level correlated with poor
survival rate, advanced pathological staging, and increasing
histological grade. It is probably because of the different sensitivity
between the two methods for detecting mRNA and protein (Shariat
et al, 2003) or of the different stability between UHRF1 mRNA and
UHRF1 protein. Thus, detection of UHRF1 mRNA overexpression
in surgical specimen might be useful as a prognosis tool in kidney
cancer, but immunohistochemical staining of UHRF1 in the cancer
may not be useful.
Because one of upstream regulators of UHRF1 is p53, we
examined correlation between expression of UHRF1, p53, and p21,
which is a downstream gene of p53, by immunohistochemistry and
TaqMan qRT–PCR, respectively. In the result, we observed
accumulation of stabilised p53 protein, which is probably mutated,
in cancer tissues at grades II and III except one case (Supplemen-
tary Figure 2). However, we did not observe any accumulation of
p53 in cancer tissues at grade I, although overexpression of UHRF1
was observed in this grade. There was no relationship between
expression levels of UHRF1 and p21 at the mRNA level (data not
shown). Thus, UHRF1 is much superior to p53 as a potential
diagnostic marker of bladder cancer. This result is concordant with
the fact that p53 is mutated only in 10–30% of bladder cancer
cases and is rarely mutated in kidney cancer (Tomasino et al, 1994;
Berggren et al, 2001; Lorenzo Romero et al, 2004).
Over 75% bladder tumour patients have one or more superficial
bladder tumours, and two-thirds of them will develop recurrent
disease (Lutzeyer et al, 1982), with 10–20% progressing to an
invasive phenotype (Torti and Lum, 1984). The outcome of
patients with invasive tumours remains still poor, with distant
metastasis occurring in over 50% within 2 years and an average
5-year survival of only 50% (Raghavan et al, 1990).
Thus, diagnosis of bladder cancer at non-advanced stage and
also precise estimation of the risk after the TURBT are very
important for prognosis of patients. Currently, the risk after the
surgery is estimated by a scoring system and risk tables developed
by European Organization for Research and Treatment of Cancer
(EORTC). The EORTC scoring system was developed based on the
six most significant clinical and pathological factors, which are
tumour stage, tumour grade, numbers of tumour, tumour size,
earlier recurrence rate, and presence of carcinoma in situ. Bladder
cancer patients with pTaG1 tumours (50% of all patients) are at
very low risk, and those with carcinoma in situ (CIS) or with
pT1G3 tumours are at the highest risk (15% of all patients).
Intermediate-risk patients are those with pTa/pT1 G1/G2 disease
who develop multiple recurrent cancers (35% of all patients). In
our result, although expression of UHRF1 was not associated with
numbers and size of bladder tumours, high expression of UHRF1
correlated with tumour malignancy defined by the stage and grade.
High expression of UHRF1 was also associated with high risk after
TURBT, probably because reflecting the association between high
expression of UHRF1 and stage, and/or grade. On the basis of these
results, detection of UHRF1 in tissue samples after TURBT will be
a prognostic marker of future recurrence and may help to
determine the risk.
Because UHRF1 was significantly overexpressed in the upper
tract TCCs, UHRF1 might be a useful diagnostic marker especially
for this type of tumour. The upper tract TCCs are often very
malignant when it is diagnosed, partially because it is relatively
difficult to find at an early stage. If the cancer is found at an early
stage, the prognosis of patients is improved. The development of a
sensitive urine-based detection marker is still being sought.
Examination of voided urine or bladder barbotage for exfoliated
cancer cells is useful for diagnosis of urothelial tumours anywhere
in the urinary tract, from the calyx, through the ureters, into
bladder and urethra. However, cytological interpretation can be
problematic; low cellular yields, atypia, degenerative changes,
urinary tract infections, stones and intravesical instillations
hamper a correct diagnosis. Because the current two biomarker
tests in clinical use, NMP-22 detection and BTA stat/BTA TRAK
assay, can be hampered by existence of bleeding, inflammation,
recent genitourinary tumours, and bladder stone (Dey, 2004), these
markers have not improved the traditional cytology-based bladder
cancer diagnosis largely. Thus, cytology is still the mainstay for
diagnosing bladder cancer. Because the expression of UHRF1 in
peripheral blood mononuclear cells was very low (Supplementary
Figure 3), the presence of these cells in urine would not impede the
diagnosis. In addition, expression of UHRF1 was not detected in
adjacent normal bladder tissues by immunohistochemistry. Thus,
contamination of these stromal cells also would not disturb the
diagnosis, either. Therefore, in our conclusion, an immuno-
histochemistry-based UHRF1 detection in urine sediment can be
a sensitive and cancer-specific diagnostic method, and may greatly
improve the current diagnosis based on cytology.
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